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doi:10.1016/j.jmii.2010.08.003Background: Prolonged exposure to combination antiretroviral therapy (CART) may result in
hyperlipidemia and other metabolic complications. This study aimed to evaluate the clinical,
virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART
was switched to atazanavir-containing antiretroviral regimens.
Methods: In this 48-week prospective, observational study that was conducted at desig-
nated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who
had developed hyperlipidemia after receiving CART that did not contain atazanavir were
enrolled. Antiretroviral regimens were switched to regimens containing two nucleoside
reverse-transcriptase inhibitors plus atazanavir 400 mg once daily or atazanavir 300 mg
boosted with ritonavir 100 mg once daily. The lipid profiles, including total triglycerides,
total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol,
CD4þ lymphocyte counts, and plasma HIV RNA load were determined every 3 months.t of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100,
tw (C.-C. Hung).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Atazanavir and hyperlipidemia 259Results: Sixty-six patients with hyperlipidemia were enrolled. At the end of the study,
triglyceride levels declined by 49.0% (pZ 0.0002) and total cholesterol levels by 18.1% from
baseline (p< 0.0001), whereas there were no significant changes observed for low-density
lipoprotein- and high-density lipoprotein-cholesterol levels. Mean CD4 lymphocyte count
increased from 465 cells/mL at baseline to 498 cells/mL at the end of the study, whereas
the proportion of patients with undetectable plasma HIV RNA load increased from 73.1%
to 81.7%. The regimens were well tolerated.
Conclusions: Switch to atazanavir-containing regimens that were well tolerated resulted in
significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and
virologic responses to CART.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Since combination antiretroviral therapy (CART) was
introduced in 1996, mortality and morbidity rate in HIV-
infected patients have significantly declined.1 However,
prolonged exposure to antiretroviral therapy is associated
with a multitude of metabolic complications, such as insulin
resistance, diabetes mellitus, dyslipidemia, and abnormal
fat distribution.2e6 Among the three classes of anti-
retroviral therapy that were available in the first decade of
CART, protease inhibitors (PIs) played a major role in the
development of metabolic adverse events, notably hyper-
lipidemia.7,8 The frequency of PI-associated hyperlipidemia
ranged from 28% to 80%; hypertriglyceridemia was the most
common presentation that ranged from 40% to 80%, fol-
lowed by hypercholesterolemia that ranged from 10% to
50%, depending on the study populations and duration and
types of antiretroviral regimens prescribed.5,9e15 The inci-
dence of hypertriglyceridemia is significantly higher in
patients treated with antiretroviral regimens containing
ritonavir compared with other regimens not containing
ritonavir.10 The mechanisms of PI-related dyslipidemia
were not fully understood and several pathways were
proposed, such as the homology of HIV-1 protease and
cytoplasmic retinoic acid-binding protein type 1 and low-
density lipoprotein (LDL) receptor-related protein, which
are the proteins involved in lipid metabolism, suppression
of adipogenesis and increased lipolysis, reduced triglyc-
eride storage and increased circulating triglyceride levels,
or suppression of proteasome-induced degradation of
apolipoprotein B in hepatocytes.11,16e18
In association with impaired glucose tolerance and new-
onset diabetes mellitus that may occur in 35% and 3% to 5%,
respectively, in PI-treated HIV-infected patients,3 hyper-
lipidemia may increase risk of myocardial infarction and
morbidity and mortality.7,19 Although adding lipid-lowering
agents is an option to improve lipid profiles in HIV-infected
patients with dyslipidemia, there were several concerns,
such as drug-drug interactions between lipid-lowering
agents and PI, rhabdomyolysis, and cost increment.15
Atazanavir is a novel azapeptide PI that is less frequently
associated with insulin resistance and dyslipidemia.20e23 In
this study, we aimed to evaluate the effectiveness and
safety of atazanavir-containing regimens in HIV-infected
patients who had developed hyperlipidemia after exposure
to other antiretroviral regimens.Patients and methods
Study design, populations, and evaluations
This was a 48-week, prospective, observational study. HIV-
infected patients with hyperlipidemia who were followed at
the designated hospitals for HIV care in Taiwan were eligible
for enrollment from January 21, 2005 to November 18, 2005.
Inclusion criteria were age 18 years, estimated therapeutic
adherence 90% (evaluated by patients’ self report and
frequency of missing previous clinic appointments), and
taking PI or non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based antiretroviral regimens with dyslipidemia.
Dyslipidemia was defined as triglyceride>250 mg/dL or total
cholesterol>240 mg/dL. Exclusion criteria were any changes
to the nucleoside reverse-transcriptase inhibitors (NRTI) that
were known to affect lipid levels or addition of other lipid-
lowering agents. Data collected for each patient at baseline
includeddemographic characteristics,medical history, family
history, smoking history, antiretroviral therapy prescribed
before the enrollment, other concomitant medications,
physical findings, CD4þ lymphocyte counts, plasma HIV RNA
load, and hematological and biochemistry tests.
The subjects were switched to regimens containing
atazanavir 400 mg or atazanavir 300 mg boosted with rito-
navir 100 mg once daily without changing backbone NRTI.
After enrollment, medication adherence, CD4þ lymphocyte
counts, HIV RNA load, and hematological and biochemistry
tests were assessed every 3 months during the 48-week
study period. All the blood samples were collected in the
fasting state. The biochemistry examinations included
renal function, liver function, glucose, total cholesterol,
triglyceride, high-density lipoprotein cholesterol, and LDL
cholesterol. Plasma HIV RNA load and CD4 cell counts was
quantified by the Cobas Amplicor HIV-1 Monitor Test,
version 1.5, (Roche Diagnostics Corporation, Indianapolis,
IN, USA) and FACSFlow (BD FACS Calibur, Becton Dickinson,
CA, USA), respectively. Undetectable plasma HIV RNA viral
load was defined as <400 copies/mL.
The primary endpoint was to evaluate the proportion of
patients achieving normal lipid profiles after switch to an
atazanavir-containing regimen, whereas the secondary
endpoint was to evaluate the safety and immunologic and
virologic responses after switch. The study was approved by
the Research Ethics Committee of each participating
hospital and all subjects gave written informed consent.
260 C.-L. Lu et al.Management of adverse events or intolerance
Toxicitiesweregradedaccording to themodifiedWorldHealth
Organization criteria: scale of 1 to 4. Subjects withmore than
Grade 2 adverse events or severe isolated hyperbilirubinemia
(bilirubin levels was greater than five times of the upper limit
of normal) would be withdrawn from the study.
Statistical analysis
Changes from baseline were calculated for lipid values,
total bilirubin level, CD4 counts, and plasma HIV RNA loads.
Qualitative baseline characteristics were compared using
the Chi-square tests. Continuous variables were expressed
as mean values with standard deviation. The statistical
analysis was performed by SAS software (Version 6.2, SAS
Institute, Cary, NC). All the tests were two-sided and a p
value less than 0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 66 HIV-infected patients with hyperlipidemia
were enrolled. Table 1 summarizes the baselineTable 1 Baseline characteristics of 66 patients receiving ataza
Variables
Age (mean, yr)
Male sex, n (%)
Positive HBsAg, n (%)
Positive anti-HCV antibody, n (%)
CD4 count before switch, mean (SD), cells/mL
CD4 count>350 cells/mL, n (%)
Log HIV RNA viral load before switch, mean (SD), log10 copies/mL
HIV RNA viral load <400 copies/mL, n (%)
Baseline triglycerides, mean (SD), mg/dL
Baseline total cholesterol, mean (SD), mg/dL
Baseline total bilirubin, mean (SD), mg/dL
Receiving lipid-lowering agents, n (%)
NRTI before switch, n (%)
AZTþ 3TC
D4Tþ 3TC
Other combinations
ddIþ 3TC
ABCþ 3TC
ABCþ ddI
NNRTI before switch, n (%)
Efavirenz
Nevirapine
PI before switch, n (%)
Lopinavir/ritonavir
Indinavir/ritonavir
Nelfinavir
Indinavir
Saquinavir/ritonavir
Other combinations
3TCZ lamivudine; ABCZ abacavir; AZTZ zidovudine; D4TZ stavu
HCVZ hepatitis C virus; PIZ protease inhibitor; SDZ standard deviacharacteristics of the patients. There were 63 (95.5%)
males and 3 (4.5%) females, and their mean age was 42.1
years. Five patients (7.6%) were positive for hepatitis B
surface antigen and 2 (3.0%) for anti-hepatitis C virus
antibody. The baseline CD4 count before switch was 468
cells/mL; 41 patients (62.1%) had a CD4 count higher than
350 cells/mL. Forty-nine patients (74.2%) had undetectable
plasma HIV RNA load before switch. Before switch, 38
patients (57.6%) were taking PI-containing regimens and 28
(42.4%) were taking NNRTI-containing regimens before
enrollment. Regarding the backbone NRTI combinations, 27
patients (42.9%) were on zidovudine plus lamivudine (3TC);
12 (19.0%) were on stavudine plus 3TC; 5 (7.9%) were on
didanosine plus 3TC; 5 (7.9%) were on abacavir plus 3TC;
and 1 (1.6%) was on abacavir plus didanosine. In 16 (24.2%),
NRTI prescribed were not described in the medical records
before switch. Sixty-four patients (97.0%) were switched to
regimens containing 400 mg of atazanavir, and 2 (3%) were
switched to 300 mg of atazanavir boosted with 100 mg of
ritonavir.
Changes of lipid profiles
Before switch, baseline mean triglyceride level was
792 mg/dL (range: 83e5,933) and total cholesterol was
240.7 mg/dL (range: 134e690). Twenty-five patientsnavir-containing combination antiretroviral therapy
Value
42.1
63 (95.5)
5 (7.6)
2 (3.0)
468 (271)
41 (62.1)
3.1 (1.2)
49 (74.2)
792.0 (838.0)
240.7 (96.1)
0.7 (0.4)
25 (37.9)
58 (87.9)
27 (40.9)
12 (18.1)
8 (12.1)
5 (7.6)
5 (7.6)
1 (1.5)
28 (42.4)
25 (37.9)
3 (4.5)
38 (57.6)
19 (28.8)
9 (13.6)
5 (7.6)
3 (4.5)
1 (1.5)
1 (1.5)
dine; ddIZ didanosine; HBsAgZ hepatitis B surface antigen;
tion.
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Twelve months after switch to atazanavir-containing regi-
mens, mean triglyceride level declined by 49.0%, from
792.0 to 399.4 mg/dL (pZ 0.0002) (Fig. 1A), and total
cholesterol level by 18.1%, from 240.7 to 196.2 mg/dL
(p< 0.0001) (Fig. 1B). Twenty-four patients (36.4%) ach-
ieved triglyceride levels less than 250 mg/dL and 48
patients (72.7%) achieved total cholesterol levels less than
240 mg/dL after switch. The most significant decreases
were observed between 3 and 6 months after switch.
Although there was an increase of total mean cholesterol
level 9 to 12 months after switch, this level was still
significantly lower than that at baseline. Contrary to the
findings of significant improvement of triglyceride and total
cholesterol level after switch, there was no significant
changes in LDL (pZ 0.43) and high-density lipoprotein
cholesterol (pZ 0.61) levels.Figure 1. (A) Evolution of triglyceride levels (mg/dL) after
switch to atazanavir-containing combination antiretroviral
therapy during the study period. Top and bottom lines repre-
sent minimum and maximum values of triglyceride levels of the
patients at different time points. The upper and lower end of
the box represent first quartile and third quartile, respectively,
whereas the bar and cross in the box indicates median and
mean value, respectively. (B) Evolution of total cholesterol
levels (mg/dL) during the study period.Safety
Nine patients were withdrawn from the study during the
study period, eight because of adverse effects of atazana-
vir, including five (7.6%) patients who developed hyper-
bilirubinemia greater than 5 mg/dL, one (1.5%) patient who
had elevation of aminotransferases from 73 to 500 U/L
after 41 days of CART containing atazanavir 400 mg daily,
and two (3.0%) had skin rashes. Compared with baseline
bilirubin levels, there was a significant increase in total
bilirubin levels from 0.75 to 1.79 mg/dL after switch to
atazanavir-containing regimens (p< 0.001) and this
increase could be observed during the first 3 months of
switch. The evolution of total bilirubin level is shown in
Fig. 2.
Clinical, virologic, and immunologic responses after
switch
Serial changes of CD4 counts are shown in Fig. 3. At base-
line, 60 patients (90.9%) had a CD4 count greater than 200
cells/mL and 41 patients (62.1%) had a CD4 count greater
than 350 cells/mL. There were no significant changes of CD4
counts after switch to atazanavir-containing regimens
during the 48-week study period, whereas a significant
reduction of plasma HIV RNA load was observed in the first 6
months after switch. The percentage of patients who had
undetectable plasma HIV RNA load increased from 73.1% to
81.7%. After switch, no patients who had achieved unde-
tectable plasma HIV RNA load experienced virologic
rebound. None of the patients developed opportunistic
infections or malignancies during the study period.
Discussion
Atazanavir is a PI known for a lower incidence of dyslipi-
demia compared with other PI and efavirenz.24e26 The
reasons why atazanavir had less dyslipidemia were not
clearly understood. Switching to atazanavir-containing
regimen has been proposed as a measure to improve lipid
profiles in patients who develop dyslipidemia caused byFigure 2. Evolution of total bilirubin levels (mg/dL) during
the study period.
Figure 3. Evolution of CD4 counts (cells/mL) during the study
period.
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NNRTI or addition of lipid lowering agents.27e31
Our study demonstrated that HIV-infected patients who
had developed hyperlipidemia after CART had improvement
of lipid profiles after switch to atazanavir-containing regi-
mens throughout the 48-week study period, and the
reduction could be seen as early as the first 3 months after
switch in our study. Furthermore, virologic response also
improved after switch without encountering significant
adverse events. All the studies showed more significant
decrease in triglyceride levels compared with the change in
total cholesterol levels. The findings of in vitro studies that
atazanavir does not induce triglyceride synthesis in HepG2
cells as other PI may explain the reason why significant
improvement of triglyceride levels occurs.32,33 Although
sustained favorable effect on lipid profiles has been
reported in a study conducted for greater than 72 weeks,34
we observed a rebound in total cholesterol levels in the
later study period, which suggests that other factors, such
as diet and life style, should also be taken into account to
maintain the favorable effect of atazanavir on the lipid
levels.
Soriano et al.27 demonstrated that unboosted atazana-
vir-containing regimens had more favorable lipid profiles
than atazanavir boosted with ritonavir. In our study, we
were not able to compare the extent to which lipid levels
may decline between boosted and unboosted atazanavir-
containing regimens because only two were switched to
boosted atazanavir-containing regimens.
In our study, 60% of the patients had a triglyceride level
greater than 250 mg/dL after switch for 48 weeks. Other
than diet and life style, genetic factors may also play
a role. There were several studies suggesting that single-
nucleotide polymorphism on APOA5 is associated with
variations of plasma lipid levels, especially hyper-
triglyceridemia.35,36 In Chinese populations, c.553G>T
polymorphism in APOA5 may present as a prognostic indi-
cators of hypertriglyceridemia.37 Decreased triglyceride
metabolism because of this genetic background causes
extremely high triglyceride even after switch to atazanavir-
containing regimens.Most of the patients in this study had achieved good viral
suppression before switch. After switch, we did not observe
any immunologic and virologic failures. Our study results
are comparable with those of The Switch to Another
Protease Inhibitor study, which demonstrated that patients
who switched to atazanavir-containing regimens had
a lower rate of virologic rebound than those who continued
other comparator PIs.31 Other studies that compared the
efficacy of atazanavir with that of other PI also showed
same results.27e29,38 Therefore, switching to atazanavir-
containing regimen can be considered safe for patients who
had good virologic suppression under non-atazanavir-con-
taining regimens.
Atazanavir is a competitive inhibitor of the uridine
diphosphate-glucuronosyl transferase 1A1 enzyme, which
may result in unconjugated hyperbilirubinemia, the most
common side effect in our study.34,39 This mechanism is
similar to the pathogenesis of Gilbert syndrome, which is of
little clinical significance because this effect is neither
hepatotoxic nor irreversible.40,41 Several studies have
demonstrated that the frequency of atazanavir-containing
regimens had a low frequency of hepatotoxicity even in
patients with hepatitis B and/or C coinfection.41,42 Besides,
the short-term effectiveness of antiretroviral agents in HIV-
infected patients with hepatitis B and/or C coinfection was
similar to patients without coinfection.41 Therefore, ata-
zanavir-containing regimens seem to be safe in patients
with hepatitis B or C coinfection.
In conclusion, atazanavir-containing antiretroviral
therapy had favorable effects on plasma triglyceride and
cholesterol levels without increasing immunologic or viro-
logic failure. Switch to atazanavir-containing regimen could
be considered in patients who develop severe dyslipidemia
because of other PI- or NNRTI-based regimens.
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